Valneva SE (NASDAQ:VALN) Sees Significant Growth in Short Interest

Valneva SE (NASDAQ:VALNGet Free Report) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 71,800 shares, an increase of 27.5% from the April 30th total of 56,300 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 13,400 shares, the short-interest ratio is currently 5.4 days.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. increased its stake in Valneva SE (NASDAQ:VALNFree Report) by 2.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities & Exchange Commission. 11.39% of the stock is owned by institutional investors.

Valneva Stock Up 1.9 %

NASDAQ:VALN opened at $9.07 on Friday. Valneva has a fifty-two week low of $6.58 and a fifty-two week high of $17.05. The stock has a market capitalization of $631.57 million, a P/E ratio of -22.12 and a beta of 2.22. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64. The company’s 50-day simple moving average is $8.09 and its 200-day simple moving average is $8.85.

Valneva (NASDAQ:VALNGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.12. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. The business had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $95.80 million. On average, equities analysts anticipate that Valneva will post -0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VALN has been the topic of several recent research reports. Guggenheim dropped their target price on shares of Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, March 22nd. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Valneva in a report on Friday.

Read Our Latest Stock Report on VALN

About Valneva

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

Featured Articles

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.